Trial Information

Summary: Randomized phase III study for stage II colon cancer at high risk for recurrence Comparing 5-FU, leucovorin and Oxalplatin versus 5-FU, leucovorin, oxaliplatin and bevacizumab to determine prospectively the prognostic value of molecular markers

A marker evaluation of your tumor will be done if it demonstrates you to be at low-risk for tumor recurrence, then you will have regular follow-up to monitor your health, but will not receive any further treatment for the cancer including chemotherapy.

If the tumor marker shows high-risk for tumor recurrence the you will be randomized into one of two study groups.

You will also receive bevacizumab on day 1 every two weeks

Patient Inclusion Criteria:

• Stage II colon adenocarcinoma
• Patients must have greater and/or equal 8 lymph nodes evaluated
• Patients must not have had any systemic or radiation therapy
• Patients must be 18 or older
• Patients must have good performance status

Patient Exclusion Criteria:

• Surgery past 60 days from day of registration
• Pregnant and/or nursing
• Patients with non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude them from receiving the drugs
• Patients with psychiatric or addictive disorders

Primary Outcomes:

If you would like to learn more about participating in this study, please send an e-mail message using the form below.